Abstract:Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induction chemotherapy and allogeneic stem cell transplantation (alloHSCT), this effect has been largely mitigated in older and less fit patients as well as those with adverse-risk disease characteristics. However, the last 10 years has been marked by major advances in the molecular profiling of AML characterized by a deeper understanding of disease pathobiology and therapeutic vulnerabilities. In this regard, the classification of AML subtypes has recently evolved from a morphologic to a molecular and genetic basis, reflected by recent updates from the World Health Organization and the new International Consensus Classification system. After years of stagnation in new drug approvals for AML, there has been a rapid expansion of the armamentarium against this disease since 2017. Low-intensity induction therapy with hypomethylating agents and venetoclax has substantially improved outcomes, including in those previously considered to have a poor prognosis. Furthermore, targeted oral therapies against driver mutations in AML have been added to the repertoire. But with an accelerated increase in treatment options, several questions arise such as how to best sequence therapy, how to combine therapies, and if there is a role for maintenance therapy in those who achieve remission and cannot undergo alloHSCT. Moreover, certain subtypes of AML, such as those with TP53 mutations, still have dismal outcomes despite these recent advances, underscoring an ongoing unmet need and opportunity for translational advances. In this review, we will discuss recent updates in the classification and risk stratification of AML, explore the literature regarding low-intensity and novel oral combination therapies, and briefly highlight investigative agents currently in early clinical development for high-risk disease subtypes.

EnABLing Tumor Growth and Progression: Recent progress in unraveling the functions of ABL kinases in solid tumor cells.

ABL Kinases Promote Breast Cancer Osteolytic Metastasis by Modulating Tumor-Bone Interactions Through TAZ and STAT5 Signaling

Role of Phosphatidylinositol 3-Kinase and Specific Protein Kinase B Isoforms in the Suppression of Apoptosis Mediated by the Abelson Protein-tyrosine Kinase

Inactivation of ABL kinases suppresses non-small cell lung cancer metastasis.

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia

ALK: a tyrosine kinase target for cancer therapy

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia

Oncogenic Forms of ABL Family Kinases

Structure-guided drug design targeting Abl kinase: how structure and regulation can assist in designing new drugs

Supplementary Data Legends from Cervical Cancer Growth is Regulated by a C-Abl–plk1 Signaling Axis

Inhibition of Abl Kinases by Intramolecular and Intermolecular Interactions: A Lesson from Structure Studies and CML Therapy

Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia

Genetic mutations in chronic myelogenous leukemia: when to check and what to do?

Exploiting cellular pathways to develop new treatment strategies for AML

New ABL1 Kinase Domain Mutations in BCR::ABL1‐Positive Acute Lymphoblastic Leukemia

Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia

Control of Ph+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors

Targeting BCR-ABL1-positive leukaemias: a review article

Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors

Recent advances in targeted therapies in acute myeloid leukemia

Current status and research directions in acute myeloid leukemia